TAKARA BIO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,015 JPY | +0.10% |
|
+6.17% | -18.93% |
| Mar. 18 | Takara Bio Inc.(TSE:4974) dropped from FTSE All-World Index | CI |
| Feb. 15 | Takara Bio's Attributable Income Falls 98.9% in Fiscal Nine Months | MT |
| Sales 2024 * | 44.82B 283M | Sales 2025 * | 47.45B 300M | Capitalization | 122B 772M |
|---|---|---|---|---|---|
| Net income 2024 * | 2.06B 12.99M | Net income 2025 * | 3.74B 23.59M | EV / Sales 2024 * | 2.73 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.58 x |
| P/E ratio 2024 * |
59.4
x | P/E ratio 2025 * |
32.7
x | Employees | 1,793 |
| Yield 2024 * |
1.51% | Yield 2025 * |
1.81% | Free-Float | 39.09% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.10% | ||
| 1 week | +6.17% | ||
| Current month | +4.64% | ||
| 1 month | +3.47% | ||
| 3 months | -19.06% | ||
| 6 months | -21.98% | ||
| Current year | -18.93% |
1 week
970.00
1 030.00
1 month
931.001 030.00
Current year
931.001 290.00
1 year
931.001 790.00
3 years
931.003 350.00
5 years
931.003 535.00
10 years
900.003 535.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | 68 | 14-05-31 | |
Koichi Nakao
PSD | President | 61 | 02-03-31 |
Takuya Kakemi
ADM | Chief Administrative Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hisashi Omiya
CHM | Chairman | 80 | 02-03-31 |
Masanobu Kimura
BRD | Director/Board Member | 60 | 13-04-30 |
Koichi Nakao
PSD | President | 61 | 02-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.00% | 23 M€ | +1.75% | - | |
| 0.22% | 8 M€ | +5.80% | ||
| 0.06% | 60 M€ | +14.42% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 1,015 | +0.10% | 131,600 |
| 24-04-25 | 1,014 | -0.49% | 347,800 |
| 24-04-24 | 1,019 | +1.09% | 317,900 |
| 24-04-23 | 1,008 | +1.92% | 269,700 |
| 24-04-22 | 989 | +3.45% | 321,100 |
Delayed Quote Japan Exchange, April 26, 2024 at 02:00 am EDT
More quotes
TAKARA BIO INC. is a Japan-based company principally engaged in bio-industry support business and gene medicine business. The Company operates in three business segments. Bioindustry Support segment provides reagents for research (genetic engineering reagents, cell engineering reagents, protein engineering reagents), scientific instruments, contract services and license fees for gene related patents to research institutes, such as universities and companies where biotechnology research and development are conducted. Gene Medicine segment provides gene therapy-related development and sale licensing fees and trial products as an application field of genetic engineering technology and cell engineering technology which is core technology cultivated in development of research reagents. Medical Food and Biotechnology segment provides health food and health food research and development services, license fees for health food related patents, as well as license fees for mushrooms.
Calendar
2024-05-09
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1,015
JPY
Average target price
1,600
JPY
Spread / Average Target
+57.64%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.93% | 785M | |
| +1.51% | 42.59B | |
| +8.57% | 40.65B | |
| +49.22% | 40.57B | |
| -12.36% | 26.77B | |
| +8.92% | 24.81B | |
| -25.13% | 18.17B | |
| +29.17% | 12.05B | |
| -3.12% | 11.7B | |
| +6.35% | 11.1B |
- Stock Market
- Equities
- 4974 Stock
